Insights › Market reaction

How Merck Stock Reacted to Its Q2 2026 Earnings, Measured Minute by Minute

Every earnings headline that crossed for Merck on 4 August 2026, with the price reaction measured from the instant each line printed.

Published in ET: Feed time in ET: Earnings MRK +2.03% (15m)
  • Measured from the print at 10:30 UTC on 4 August 2026: $128.39 to $131.00 in fifteen minutes, +2.03%.
  • Every headline row is measured from its own instant, so the lines can be compared directly.
  • One-minute versus fifteen-minute readings show how fast the report was actually priced.

When Merck's numbers crossed at 10:30 UTC, the tape agreed with them: $128.39 to $131.00 in fifteen minutes, +2.03% measured from the print.

This page is the measured anatomy of that print on 4 August 2026: every earnings-related headline that crossed for Merck, in order, each with the price reaction measured from its own instant.

The print, row by row

CrossedHeadline as recorded15-min move from that instantVolume vs normal
10:30 UTCMerck & Co. Inc. (MRK) Q2 2026 (USD) Adj. EPS -0.13 (exp. -0.27), Revenue 16.6bln (exp. 16.37bln), Current FY EPS 2.66-2.76 (exp. 2.76), Current FY Re+2.03%
10:36 UTCMerck & Co Lowers FY2026 Adj EPS Guidance from $5.04-$5.16 to $2.66-$2.76 vs $2.76 Est; Raises FY2026 Sales Guidance from $65.800B-$67.000B to $66.300+0%
10:43 UTCReported: $MRK Merck & Co Q2 Earnings Sales $16.61B, est. $16.35B | Keytruda rev. $8.37B, +5.2% y/y, est. $8.04B | Gardasil rev. $1.17B, est. $1.12B-1.25%

The shape matters as much as the size. One minute in, the stock had moved -2.09%; by minute fifteen the sign had flipped to +2.03%. The first algorithmic read and the considered read disagreed, and the considered read won — a reversal inside the first quarter-hour, which is the single strongest argument for measuring at more than one horizon.

Which line actually moved it

Each row above is measured from its own instant — the price immediately before that specific headline crossed — so the rows can be compared directly. The largest single reaction, +2.03%, belongs to the 10:30 UTC line. By the time the 10:36 UTC line arrived, the measured response was +0% — the marginal information in each successive headline decays fast, and the decay is measurable.

Did the first read hold?

It did. By the close of that session, Merck stood at +0.18% against the prior close — the same direction the first fifteen minutes priced. The instant read and the considered read agreed.

The cleanest case: better numbers, higher price, and a measurable window in which that repricing happened. The volume column shows how much participation confirmed it.

How these numbers were measured

We record the price of the instrument immediately before each headline crosses our tape, then again one minute and fifteen minutes later, together with traded volume against that instrument's own normal. Every figure on this page comes from those recordings — the timestamps are the actual instants the lines crossed. Nothing here is an estimate, a close-to-close change, or a model's guess. The method, the gates every page must pass, and how we correct errors are documented in our editorial standards.

How did Merck stock react to its Q2 2026 earnings?

Measured from the instant the first headline crossed on 4 August 2026 at 10:30 UTC, Merck moved from $128.39 to $131.00 over the following fifteen minutes — +2.03%. The measurement starts at the print itself, not at the open, so it isolates the report's own effect.

How fast was the report priced in?

One minute after the print the measured move was -2.09%; at fifteen minutes it was +2.03%. The gap between those two figures is the pricing-in window — how long the market took to finish reading.

Which headline moved Merck the most?

The 10:30 UTC line carried the largest measured reaction of the sequence at +2.03%. Later lines measured progressively less — repeat information decays within minutes.

Sources

  • Merck (MRK) earnings Q2 2026 - CNBC
    Merck reported Q2 2026 results on 4 August 2026: sales $16.6bn up 5% ahead of the $16.41bn consensus, an adjusted loss of $0.13 per share against a $0.27 loss forecast, and KEYTRUDA family sales of $8.4bn up 4%.
  • Our Q2 2026 financial results - Merck
    Merck reported Q2 2026 results on 4 August 2026: sales $16.6bn up 5% ahead of the $16.41bn consensus, an adjusted loss of $0.13 per share against a $0.27 loss forecast, and KEYTRUDA family sales of $8.4bn up 4%.

Never miss the next market-moving story

Seven market specialists, with experience dating back to 2006, watch global markets and U.S. stocks of every size. Start Pro to get the full live feed, clear context, measured price moves, search, watchlists, and alerts.

Start Pro — $29 for 7 days Watch MRK live -- free
See live news
The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Wide coverageGlobal markets and every size of U.S. stock Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources
Start Pro — $29 for 7 days View the live feed $29 today for 7 days. Then renews at the selected plan unless cancelled. Information only—no trade calls.